Dr. Michael Fricker will present an update on Anti-IL-4R Targeted Therapy for Severe Asthma. He will focus on a recent LANCET article by Sally Wenzel et al titled “Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial”.
Date: 11th May
Time: 3:30 pm
Location: Cameron Room, Level 4, HMRI
If you are interested in attending and would like to receive information about future journal club session directly, please RSVP firstname.lastname@example.org
Next Session: 08 June @ 3:30 PM, Moss Room, HMRI
Presenter: Krystelle Godbout